Abstract
Ixazomib is a next generation oral proteasome inhibitor with proven efficacy in relapsed AL amyloidosis. Whilst the combination of ixazomib, lenalidomide and dexamethasone (IRd) is established in multiple myeloma, its role in AL amyloidosis is undetermined. We present the UK experience of this regimen in the treatment of relapsed refractory AL amyloidosis. Method Forty patients treated with IRd, between 2016 and 2019, were identified from the database at the UK National Amyloidosis Centre. Haematological and disease responses were defined as per the international amyloidosis consensus guidelines.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
